康复新液联合埃索美拉唑镁治疗消化道溃疡的临床研究

Clinical trial of Kangfuxin plus esomeprazole in the treatment of patients with peptic ulcer

目的观察康复新液联合埃索美拉唑镁对消化道溃疡的临床疗效及其对血清血管内皮细胞生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)的影响。方法 80例消化道溃疡患者随机分为试验组和对照组,每组40例。对照组患者口服埃索美拉唑镁20 mg,阿莫西林1.0 g,克拉霉素0.5 g,每天2次,14d后,仅服用埃索美拉唑镁20 mg,每天2次;试验组患者在此基础上口服康复新液10 m L,每天3次,2组均治疗4周。比较2组患者的临床疗效、幽门螺旋杆菌根除情况,观察2组患者治疗前后血清VEGF、bFGF的变化情况及药物不良反应的发生情况。结果治疗后,试验组总有效率为97.50%(39/40例),对照组总有效率为82.50%(33/40例),差异有统计学意义(P<0.05)。试验组幽门螺旋杆菌根除率为95.00%(38/40例),对照组幽门螺旋杆菌根除率为92.50%(37/40例),差异无统计学意义(P>0.05)。治疗后,试验组VEGF为(174.05±15.41)pg·mL^(-1),bFGF为(142.72±16.73)pg·mL^(-1),对照组VEGF为(153.24±16.23),bFGF为(131.24±15.44)pg·mL^(-1),差异有统计学意义(P<0.05)。试验组出现便秘2例,面红口干1例,药物不良反应发生率为7.50%(3/40例);对照组出现便秘1例,面红口干1例,药物不良反应发生率为5.00%(2/40例,P>0.05)。结论康复新液联合埃索美拉唑镁治疗消化道溃疡,可显著提高血清VEGF、bFGF水平,改善临床疗效,且安全性较好。

Objective To evaluate the clinical efficacy of Kangfuxin plus esomeprazole in patients with peptic ulcer and the impact on serum vas- cular endothelial growth factor（VEGF） and basic fibroblast growth factor （bFGF）. Methods Eighty patients with peptic ulcer were randomly di- vided into treatment group and control group, 40 cases in each group. Control group was orally given esomeprazole 20 rag, amoxicillin 1.0 g, elarithromycin O. 5 g, twice a day, after 14 d, taking esomeprazole 20 mg only, twice a day. On the base of control group, treatment group was given Kangfuxin 10 mL orally, three times a day. All patients were trea- ted for 4 weeks. The clinical efficacy, helicobacter pylori eradication, levels of VEGF, bFGF and adverse drug reactions were compared be- tween the two groups. Results After treatment, total effective rate in treatment group and control group were 97.50% （39/40） and 82.50% （33/40）, respectively （ P 〈 0. 05 ）. Helicobacter pylori eradication rate in treatment group was 95.00% （38/40）, had no statistically significance with 92.50% （37/4.0） in control group （P 〉 O. 05）. The levels of VEGF and bFGF were （ 174. 05 ± 15.41）,（142.72±16.73） pgo mL-1 in treatment group, and（153.24 ±16.23）,（131.24±15.44） pg · mL-1 in control group （ P 〈0. 05 ）. There were 2 eases of constipation, 1 case of red face and dry mouth in treatment group, the incidence rate of adverse drug reactions was 7.50% （3/40）. Control group had 1 case of constipation, 1 ease of dry mouth with red face, the imndence rate of adverse drug reactions was 5.00% （ 2/40, P 〉 O. 05 ）. Conclusion Kangfuxin plus esomeprazole had good clinical effect in patients with peptic ulcer, can significantly increase the levels of serum VEGF, bFGF, and sMety.